Global Enzyme Linked Immunospot Assays Market, By Test Type (Sandwich ELISA, Indirect ELISA, Multiple and Portable ELISA, Competitive ELISA), Application (Immunology, Inflammation, Infectious Diseases, Cancer, Protein Quantitation, Other) – Industry Trends and Forecast to 2029
Enzyme Linked Immunospot Assays Market Analysis and Size
According to the Globocan 2020, there were roughly 9,958,133 cancer-related deaths worldwide and an estimated 19,292,789 new cancer cases that were identified. Additionally, the International Agency for Research on Cancer (IARC) predicts that by 2040, there will be 16.3 million cancer-related deaths globally and 27.5 million new instances of cancer. The enzyme linked immunospot assays demand is anticipated to be driven by the rising number of cancer cases.
Data Bridge Market Research analyses that the enzyme linked immunospot assays market which was USD 493.77 million in 2021, would rocket up to USD 711.93 million by 2029, and is expected to undergo a CAGR of 4.68% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Enzyme Linked Immunospot Assays Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Test Type (Sandwich ELISA, Indirect ELISA, Multiple and Portable ELISA, Competitive ELISA), Application (Immunology, Inflammation, Infectious Diseases, Cancer, Protein Quantitation, Other)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Thermo Fisher Scientific Inc. (U.S.), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Merck KGaA (Germany), RayBiotech Life Inc. (U.S.), R&D Systems, Inc. (U.S.), AESKU.GROUP GmbH & Co. KG (Germany), Eurofins Scientific (Luxembourg), Biogenuix (India), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Danaher (U.S.), Sysmex Corporation (Japan), PerkinElmer Inc. (U.S.), Agilent Technologies Inc. (U.S.)
The enzyme linked immunospot (ELISpot) assays is a fundamental tool in cellular immunology, providing both quantitative and qualitative information on cellular cytokine responses to defined antigens. In order to identify CD8+ T cells that are specific to an epitope, the enzyme-linked immunospot (ELISPOT) assays is a sensitive immunologic technique that measures cytokine release on a single-cell basis. A putative antigenic peptide is delivered to CD8+ T lymphocytes via MHC-I on antigen-presenting cells (APCs). ELISpot assays are quicker, more trustworthy, and less expensive than other functional assays (e.g., ICS). They are especially well suited for screenings because of their great sensitivity and simplicity of use.
Enzyme Linked Immunospot Assays Market Dynamics
- Increase in diagnostic technologies
According to the World Health Organization, over 354 million individuals worldwide are estimated to have hepatitis B or C infections in 2020. The need for a diagnosis arise due to the rising occurrence of infectious diseases. The expansion of the market is related to the rising use of cutting-edge diagnostic technologies for illness screening, such as enzyme linked immunosorbent assays.
- Rising chronic diseases
According to the World Health Organization's December 2020 report, the major chronic diseases currently account for over 60% of all fatalities and 43% of the burden of disease globally. By 2020, it is anticipated that their share of global morbidity and mortality will reach 60% and 73 percent, respectively. Additionally, chronic diseases account for 79 percent of mortality in underdeveloped nations. Additionally, market expansion is anticipated to be fuelled by technological advancements in assay kits and analyzers for enzyme linked immunosorbent assay.
- Rising healthcare expenditure
According to the Center for Disease Control and Prevention 2021, the leading causes of mortality and disability in the United States are chronic diseases like heart disease, cancer, and diabetes. Additionally, they are primarily responsible for the USD 3.8 trillion in annual healthcare expenditures in the US. As a result of increasing healthcare costs and the incidence of chronic diseases, the market is expected to rise throughout the forecast period.
- Increase in the number of research and development activities
The market's growth is fuelled by rising number of patients with infectious diseases around the world, the proliferation of innovative and novel products, and the use of advanced technology for multiple diagnosis are expected to boost the growth of the enzyme linked immunospot assays market.
On the other hand, throughout the forecast period, the market will expand due to the launch of numerous medications that will further boost potential of the market.
On the other hand, the easy availability of alternative methods will obstruct the market's growth rate.
This enzyme linked immunospot assays market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the enzyme linked immunospot assays market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Enzyme Linked Immunospot Assays Market
Enzyme-linked immunosorbent assay (ELISA) demand has surged due to the COVID-19 all over the world. The main cause of this is the rise in infection rates, which increased the demand for accurate diagnosis. Data from the National Center for Biotechnology Information (NCBI) Journal in 2020 show that SARS-CoV-2 can be accurately detected using the enzyme-linked immunosorbent assay (ELISA). The demand for more affordable and accurate diagnosis in order to receive the right treatment is anticipated to fuel market expansion.
Global Enzyme Linked Immunospot Assays Market Scope
The enzyme linked immunospot assays market is segmented on the basis of test type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Sandwich ELISA
- Indirect ELISA
- Multiple and Portable ELISA
- Competitive ELISA
- Infectious Diseases
- Protein Quantitation
Enzyme Linked Immunospot Assays Market Regional Analysis/Insights
The enzyme linked immunospot assays market is analysed and market size insights and trends are provided by country, test type and application as referenced above.
The countries covered in the enzyme linked immunospot assays market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the enzyme linked immunospot assays market owing to the emergence in the abundance of businesses, developed healthcare foundation, and the extent of communicable disorders and the improvement of several innovative commodities.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising number of patient population along with developing of infrastructure and adoption of diagnostic tools.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Enzyme Linked Immunospot Assays Market Share Analysis
The enzyme linked immunospot assays market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to enzyme linked immunospot assays market.
Some of the major players operating in the enzyme linked immunospot assays market are:
- Thermo Fisher Scientific Inc. (U.S.)
- BD (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- bioMérieux (France)
- Merck KGaA (Germany)
- RayBiotech Life Inc. (U.S.)
- R&D Systems, Inc. (U.S.)
- AESKU.GROUP GmbH & Co. KG (Germany)
- Eurofins Scientific (Luxembourg)
- Biogenuix (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Danaher (U.S.)
- Sysmex Corporation (Japan)
- PerkinElmer Inc. (U.S.)
- Agilent Technologies Inc. (U.S.)